Discover more from Alexander COVID News-Dr. Paul Elias Alexander's Newsletter

COVID-19 and SARS-CoV-2: natural immunity; innate immunity; vaccines and immune pressure; no vaccines for children; early outpatient treatment; lockdowns; school closures and mask mandates and vaccine mandates and emergency powers and truck convoy

Over 38,000 subscribers

Dag Berild et al.: "Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries" see Table 3, stunning cardiac harms

an increased rate of coronary artery disease following Moderna vaccine; AZD1222 was associated with increased rates of cerebral venous thrombosis and thrombocytopenia in 3 Nordic countries.

Dr. Paul Alexander

Oct 30, 2022

These results add to the already accumulated strong evidence of serious cardiovascular risk (heart disease, coagulation disorders, cerebrovascular illness etc.) following use of the COVID vaccines and especially the mRNA COVID vaccines.

This self-controlled case series used individual-level data from national registries in Norway, Finland, and Denmark. Participants included individuals with hospital contacts because of coronary artery disease, coagulation disorders, or cerebrovascular disease between January 1, 2020, and May 16, 2021.’

‘265 339 hospital contacts, of whom 112 984 [43%] were for female patients, 246 092 [93%] were for patients born in 1971 or earlier, 116 931 [44%] were for coronary artery disease, 55 445 [21%] were for coagulation disorders, and 92 963 [35%] were for cerebrovascular disease.’

Key results:

‘In the 28-day period following vaccination, there was an increased rate of coronary artery disease following Moderna vaccination (RR, 1.13 [95% CI, 1.02-1.25]), but not following AZD1222 vaccination (RR, 0.92 [95% CI, 0.82-1.03]) or Pfizer vaccination (RR, 0.96 [95% CI, 0.92-0.99]).

There was an observed increased rate of coagulation disorders following all 3 vaccines (AZD1222: RR, 2.01 [95% CI, 1.75-2.31]; BNT162b2: RR, 1.12 [95% CI, 1.07-1.19]; and mRNA-1273: RR, 1.26 [95% CI, 1.07-1.47]).

There was also an observed increased rate of cerebrovascular disease following all 3 vaccines (AZD1222: RR, 1.32 [95% CI, 1.16-1.52]; BNT162b2: RR, 1.09 [95% CI, 1.05-1.13]; and mRNA-1273: RR, 1.21 [95% CI, 1.09-1.35]).

For individual diseases within the main outcomes, 2 notably high rates were observed: 12.04 (95% CI, 5.37-26.99) for cerebral venous thrombosis and 4.29 (95% CI, 2.96-6.20) for thrombocytopenia, corresponding to 1.6 (95% CI, 0.6-2.6) and 4.9 (95% CI, 2.9-6.9) excess events per 100 000 doses, respectively, following AZD1222 vaccination.’

Table 3:

SOURCE:

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793348